DOCSLIB.ORG

REVIEW Dendritic Cell-Based Vaccine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
REVIEW Dendritic Cell-Based Vaccine Leukemia (1999) 13, 653–663 1999 Stockton Press All rights reserved 0887-6924/99 $12.00 http://www.stockton-press.co.uk/leu REVIEW Dendritic cell-based vaccine: a promising approach for cancer immunotherapy K Tarte1 and B Klein1,2 1INSERM U 475, Montpellier; and 2Unit For Cellular Therapy, CHU Saint Eloi, Montpellier, France The unique ability of dendritic cells to pick up antigens and to + + and interstitial DC pick up antigens (Ag) in peripheral tissues activate naive and memory CD4 and CD8 T cells raised the and migrate to lymphoid organs through lymphatic vessels in possibility of using them to trigger a specific anti-tumor 8 immunity. If numerous studies have shown a major interest in response to inflammatory stimuli. Activated mature DC, dendritic cell-based vaccines for cancer immunotherapy in ani- which express CD1a and CD83 antigens, represent the latter mal models, only a few have been carried out in human can- stage of LC and interstitial DC maturation. According to their cers. In this review, we describe recent findings in the biology high expression of MHC class I, MHC class II and costimu- of dendritic cells that are important to generate anti-tumor cyto- latory molecules, they present, efficiently, Ag-derived peptides toxic T cells in vitro and we also detail clinical studies reporting to CD4+ and CD8+ T lymphocytes in lymph node T cell areas the obtention of specific immunity to human cancers in vivo using reinfusion of dendritic cells pulsed with tumor antigens. (Figure 1). Recently, another subset of DC was identified on Keywords: dendritic cells; cancer; immunotherapy the basis of their high expression of the interleukin-3 receptor alpha chain (IL-3R␣hi). These cells are able to migrate to lymphoid organs without any prior activation by inflamma- 9 Introduction tory stimuli. The possibility of generating DC in vitro has helped to Despite progress in chemotherapy regimens, several malig- understand their ontogeny and to further characterize their nancies remain incurable by conventional therapies. It is thus phenotype. As illustrated in Figure 2, all DC subsets originate from bone marrow CD34+ hematopoietic precursor cells fol- necessary to develop alternative strategies, in particular anti- 10–12 tumor immunotherapy. Dendritic cells (DC) play a crucial role lowing two overlapping pathways. Granulocyte–macro- in the initiation of primary immune response and are therefore phage colony-stimulating factor (GM-CSF) and tumor necrosis factor ␣ (TNF␣) are the two main cytokines necessary for DC probably the best adjuvant for anti-tumor immunity. However, 13 their very low frequency in vivo has limited research in this maturation. Stem cell factor (SCF) and Flt3 ligand (Flt3L) enhance the yield of DC generated in vitro from CD34+ field. The possibility of obtaining large numbers of DC in vitro 14 has boosted the understanding of their ontogeny and func- cells, and Flt3L-treated mice show a great increase in the number of mature DC.15 The differentiation of CD34+ cells tions. In this paper, we will briefly review the main recent ␤ features of DC characteristics that are important for cancer into LC requires, in addition, transforming growth factor 1 ␤ ␤ −/− vaccination and discuss the various strategies to vaccinate (TGF 1) since TGF 1 knockout mice are completely devoid 16 ␤ cancer patients with DC. of LC. Moreover, TGF 1 cooperate with Flt3L for the devel- opment of CD1a+ Lag+LC in vitro.17 DC can also be generated from peripheral blood CD14+ MO, at least in vitro.18–20 In the Dendritic cells: phenotype and ontogeny presence of macrophage colony-stimulating factor (M-CSF), MO are induced to differentiate into CD14+ M⌽. However, DC constitute a heterogeneous leukocyte population defined in the presence of GM-CSF and interleukin-4 (IL-4) or interleu- kin-13 (IL-13),21–23 macrophage differentiation is blocked24,25 by morphologic, phenotypic and functional criteria which dis- − + − tinguish them from monocytes (MO) and macrophages (M⌽).1 and MO differentiate into CD14 CD1a Lag immature DC. Finally, the addition of TGF␤1 leads to obtaining CD14− Although there is evidence that a lymphoid precursor can gen- + + 26 + − erate DC, T, B and NK cells,2,3 we will focus only on myeloid CD1a Lag LC. CD1a CD83 immature MO-derived DC are lineage-derived DC which are used both in vitro and in vivo induced into highly efficient Ag presenting cells (APC) (CD1a+CD83+ mature DC) in the presence of TNF␣27,28 or in to enhance specific immune response. Originally, DC were 29,30 characterized by the presence of veils, polarized lamellipodia response to CD40 ligand (CD40L) stimulation which mim- and long spiny processes that were continually being ics interaction with T lymphocytes in T cell areas of lymphoid extended and retracted thus allowing them to be highly organs. Interestingly, the phenotype of these differentiated ⌽ motile.4 As illustrated in Figure 1, three major DC populations cells can be reverted since even fully mature M can be induced into CD1a+CD83− immature DC in the presence of have been identified in vivo: Langerhans cells (LC), interstitial + − DC and activated mature DC. LC are present in skin epidermis IL-4, and vice versa, immature CD1a CD83 DC, unlike + + ⌽ and mucosae and express CD1a, the cutaneous associated mature CD1a CD83 DC, can acquire a M phenotype when 31 antigen (CLA), E-cadherin and the Lag antigen associated with GM-CSF and IL-4 are replaced by M-CSF. the presence of Birbeck granules.5–7 CD1a+ interstitial DC are The phenotype of these various DC populations is now bet- found in various organs especially liver, kidney and heart. LC ter known (Table 1). DC are defined as lineage-negative cells, ie they do not express classical T cell, B cell, NK cell and monocyte (especially CD14) markers.1,32,33 The usual DC Correspondence: B Klein, INSERM U475, 99, rue Puech Villa, 34197 markers are: CD1a which is expressed by LC, MO-derived DC Montpellier, Cedex 5, France; Fax: 33 04 67 04 18–63 and lymph node DC but not by blood DC and which is Received 8 September 1998; accepted 27 January 1999 involved in the presentation of lipid and glycolipid Ag to T Review K Tarte and B Klein 654 Figure 1 Immature DC are localized in peripheral tissues and migrate to lymphoid organs where they activate T lymphocytes. Figure 2 DC ontogeny and lineage. 33–36 44 ␣ ␤ ⌽ cells; CD83 which is present on some rare circulating ecules (Figure 3). In particular, v 5 is absent on MO/M blood DC34 and which is induced during DC maturation and this could explain why these cells are unable to present (cultured blood DC, mature MO-derived DC, lymph node Ag derived from apoptotic cells, even if they internalize apop- DC);37 CMRF-44 which is less specific than CD83 and is also totic cells very efficiently. Ag capture is optimal for immature expressed by a subset of blood DC and LC. CD83 and CMRF- dendritic cells generated from peripheral blood MO after 5– 44 have unknown functions but they are interesting for DC 7 days of culturing with GM-CSF and IL-4. When DC are positive selection.38 induced to mature in vitro, in particular in the presence of TNF␣ or CD40L stimulation, they lose their ability to internal- ize soluble Ag and apoptotic cells39,44 (Figure 3). Together Dendritic cell functions in vitro and in vivo with Ag uptake, Ag processing is also modulated during DC maturation. Ag are concentrated in MHC II compartments in Again, due to the possibility of producing DC in vitro, their immature cells and, after treatment with TNF␣, these intra- maturation and function have been extensively characterized. cellular vesicules disappear and surface MHC II expression is Immature DC are able to capture and process Ag extensively upregulated.39,45 It is now well documented that immature DC in the periphery. They can internalize soluble Ag by macropi- can process exogenous soluble proteins captured by macropi- nocytosis,39 ie uptake of large vesicules (0.5–3 ␮m), as well nocytosis for MHC class I presentation.46–48 This could explain as by endocytosis of small vesicules40 by at least two types of the cross-priming phenomenon: in vivo, MHC I-restricted receptors for Ag uptake: Fc receptor and mannose receptor. tumor Ag are presented mainly, if not exclusively, by pro- CD32 (Fc␥RII), CD64 (Fc␥RI) and mannose receptor are fessional APC (mainly DC) that have taken up Ag released by downregulated during DC maturation in vitro39,41,42 (Figure 3). dying tumor cells, rather than by the tumor cells themselves.49 LC and interstitial DC are phagocytic but to a lesser extent This is of major importance for vaccination strategies for can- than M⌽ and this capacity is lost during DC maturation.42,43 cer patients. The method of Ag capture influences its presen- Immature DC are also able to internalize apoptotic cells by tation. Endocytosis via mannose receptor seems more efficient ␣ ␤ ␣ ␤ binding them through v 5, v 3 and CD36 adhesion mol- for MHC class I presentation than endocytosis via Fc recep- Review K Tarte and B Klein 655 Table 1 Surface molecules express on DC kines, namely macrophage inflammatory protein (MIP)-1␣, MIP-1␤ and RANTES. Induction of DC maturation by CD40 Functions ligand (CD40L), TNF␣ or LPS results in a rapid downregul- ation of these receptors, allowing DC to leave inflamed Dendritic-specific markers tissues. It also results in the slower induction of CCR7, which CD1 MHC-like molecules is the receptor for MIP-3␤/EBI1 ligand chemokine (ELC) and Presentation of non-peptide Ag to T cells secondary lymphoid tissue chemokine (SLC), two chemokines CD83 Unknown function constitutively produced in lymphoid organs.
Load more

Recommended publications
  • Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy
    International Journal of Molecular Sciences Review Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy Jianguang Zhang, Huifang Zheng and Yong Diao * School of Medicine, Huaqiao University, Quanzhou 362021, Fujian, China; [email protected] (J.Z.); [email protected] (H.Z.) * Correspondence: [email protected]; Tel.: +86-595-2269-2516 Received: 15 November 2018; Accepted: 11 January 2019; Published: 14 January 2019 Abstract: Natural killer (NK) cells are innate immune cells that can be activated rapidly to target abnormal and virus-infected cells without prior sensitization. With significant advancements in cell biology technologies, many NK cell lines have been established. Among these cell lines, NK-92 cells are not only the most widely used but have also been approved for clinical applications. Additionally, chimeric antigen receptor-modified NK-92 cells (CAR-NK-92 cells) have shown strong antitumor effects. In this review, we summarize established human NK cell lines and their biological characteristics, and highlight the applications of NK-92 cells and CAR-NK-92 cells in tumor immunotherapy. Keywords: natural killer cell line; NK-92; chimeric antigen receptor; immunotherapy; tumor 1. Introduction Natural killer (NK) cells are innate immune cells that were first discovered in mice in 1975 [1]. NK cells account for approximately 10% of lymphocytes in human peripheral blood (PB). Owing to the distinct chemokine receptors expressed in NK cells, the distributions of NK cells differ among healthy tissues. Most NK cells are found in the PB, liver, spleen, and bone marrow, and a small portion are also present in the lymph nodes [2–5].
    [Show full text]
  • Tools for Cell Therapy and Immunoregulation
    RnDSy-lu-2945 Tools for Cell Therapy and Immunoregulation Target Cell TIM-4 SLAM/CD150 BTNL8 PD-L2/B7-DC B7-H1/PD-L1 (Human) Unknown PD-1 B7-1/CD80 TIM-1 SLAM/CD150 Receptor TIM Family SLAM Family Butyrophilins B7/CD28 Families T Cell Multiple Co-Signaling Molecules Co-stimulatory Co-inhibitory Ig Superfamily Regulate T Cell Activation Target Cell T Cell Target Cell T Cell B7-1/CD80 B7-H1/PD-L1 T cell activation requires two signals: 1) recognition of the antigenic peptide/ B7-1/CD80 B7-2/CD86 CTLA-4 major histocompatibility complex (MHC) by the T cell receptor (TCR) and 2) CD28 antigen-independent co-stimulation induced by interactions between B7-2/CD86 B7-H1/PD-L1 B7-1/CD80 co-signaling molecules expressed on target cells, such as antigen-presenting PD-L2/B7-DC PD-1 ICOS cells (APCs), and their T cell-expressed receptors. Engagement of the TCR in B7-H2/ICOS L 2Ig B7-H3 (Mouse) the absence of this second co-stimulatory signal typically results in T cell B7-H1/PD-L1 B7/CD28 Families 4Ig B7-H3 (Human) anergy or apoptosis. In addition, T cell activation can be negatively regulated Unknown Receptors by co-inhibitory molecules present on APCs. Therefore, integration of the 2Ig B7-H3 Unknown B7-H4 (Mouse) Receptors signals transduced by co-stimulatory and co-inhibitory molecules following TCR B7-H5 4Ig B7-H3 engagement directs the outcome and magnitude of a T cell response Unknown Ligand (Human) B7-H5 including the enhancement or suppression of T cell proliferation, B7-H7 Unknown Receptor differentiation, and/or cytokine secretion.
    [Show full text]
  • Review of Dendritic Cells, Their Role in Clinical Immunology, and Distribution in Various Animal Species
    International Journal of Molecular Sciences Review Review of Dendritic Cells, Their Role in Clinical Immunology, and Distribution in Various Animal Species Mohammed Yusuf Zanna 1 , Abd Rahaman Yasmin 1,2,* , Abdul Rahman Omar 2,3 , Siti Suri Arshad 3, Abdul Razak Mariatulqabtiah 2,4 , Saulol Hamid Nur-Fazila 3 and Md Isa Nur Mahiza 3 1 Department of Veterinary Laboratory Diagnosis, Faculty of Veterinary Medicine, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia; [email protected] 2 Laboratory of Vaccines and Biomolecules, Institute of Bioscience, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia; [email protected] (A.R.O.); [email protected] (A.R.M.) 3 Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia; [email protected] (S.S.A.); [email protected] (S.H.N.-F.); [email protected] (M.I.N.M.) 4 Department of Cell and Molecular Biology, Faculty of Biotechnology and Biomolecular Science, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia * Correspondence: [email protected]; Tel.: +603-8609-3473 or +601-7353-7341 Abstract: Dendritic cells (DCs) are cells derived from the hematopoietic stem cells (HSCs) of the bone marrow and form a widely distributed cellular system throughout the body. They are the most effi- cient, potent, and professional antigen-presenting cells (APCs) of the immune system, inducing and dispersing a primary immune response by the activation of naïve T-cells, and playing an important role in the induction and maintenance of immune tolerance under homeostatic conditions. Thus, this Citation: Zanna, M.Y.; Yasmin, A.R.; review has elucidated the general aspects of DCs as well as the current dynamic perspectives and Omar, A.R.; Arshad, S.S.; distribution of DCs in humans and in various species of animals that includes mouse, rat, birds, dog, Mariatulqabtiah, A.R.; Nur-Fazila, cat, horse, cattle, sheep, pig, and non-human primates.
    [Show full text]
  • CD2 Molecules Redistribute to the Uropod During T Cell Scanning: Implications for Cellular Activation and Immune Surveillance
    CD2 molecules redistribute to the uropod during T cell scanning: Implications for cellular activation and immune surveillance Elena V. Tibaldi*†, Ravi Salgia†‡, and Ellis L. Reinherz*†§ *Laboratory of Immunobiology and ‡Division of Adult Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, and †Department of Medicine, Harvard Medical School, Boston, MA 02115 Communicated by Stuart F. Schlossman, Dana-Farber Cancer Institute, Boston, MA, April 9, 2002 (received for review February 14, 2002) Dynamic binding between CD2 and CD58 counter-receptors on op- cells, whereas its counter-receptor CD58 is expressed on a posing cells optimizes immune recognition through stabilization of diverse array of nucleated and non-nucleated cells including cell–cell contact and juxtaposition of surface membranes at a distance APCs and stromal cells (reviewed in refs. 11 and 12). CD2 suitable for T cell receptor–ligand interaction. Digitized time-lapse functions in both T cell adhesion and activation processes (13). Ϸ differential interference contrast and immunofluorescence micros- Of note, the weak affinity of the CD2-CD58 interaction (Kd copy on living cells now show that this binding also induces T cell 1 ␮M) is associated with remarkably fast on and off rates that polarization. Moreover, CD2 can facilitate motility of T cells along foster rapid and extensive exchange between CD2 and CD58 antigen-presenting cells via a movement referred to as scanning. Both partners on opposing cell surfaces (14–16). These biophysical activated CD4 and CD8 T cells are able to scan antigen-presenting cells characteristics are reminiscent of the selectin–ligand interactions surfaces in the absence of cognate antigen.
    [Show full text]
  • Folate Receptor Β Regulates Integrin Cd11b/CD18 Adhesion of a Macrophage Subset to Collagen
    Folate Receptor β Regulates Integrin CD11b/CD18 Adhesion of a Macrophage Subset to Collagen This information is current as Christian Machacek, Verena Supper, Vladimir Leksa, Goran of September 25, 2021. Mitulovic, Andreas Spittler, Karel Drbal, Miloslav Suchanek, Anna Ohradanova-Repic and Hannes Stockinger J Immunol 2016; 197:2229-2238; Prepublished online 17 August 2016; doi: 10.4049/jimmunol.1501878 Downloaded from http://www.jimmunol.org/content/197/6/2229 Supplementary http://www.jimmunol.org/content/suppl/2016/08/17/jimmunol.150187 Material 8.DCSupplemental http://www.jimmunol.org/ References This article cites 49 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/197/6/2229.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 25, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Folate Receptor b Regulates Integrin CD11b/CD18 Adhesion of a Macrophage Subset to Collagen Christian Machacek,* Verena Supper,* Vladimir Leksa,*,† Goran Mitulovic,‡ Andreas Spittler,x Karel Drbal,{,1 Miloslav Suchanek,{ Anna Ohradanova-Repic,* and Hannes Stockinger* Folate, also known as vitamin B9, is necessary for essential cellular functions such as DNA synthesis, repair, and methylation.
    [Show full text]
  • Response Gene Expression That Modulates T Cell Induces a Differential Cytokine Tuberculosis Mycobacterium Dendritic Cells with I
    Infection of Human Macrophages and Dendritic Cells with Mycobacterium tuberculosis Induces a Differential Cytokine Gene Expression That Modulates T Cell This information is current as Response of September 24, 2021. Elena Giacomini, Elisabetta Iona, Lucietta Ferroni, Minja Miettinen, Lanfranco Fattorini, Graziella Orefici, Ilkka Julkunen and Eliana M. Coccia J Immunol 2001; 166:7033-7041; ; Downloaded from doi: 10.4049/jimmunol.166.12.7033 http://www.jimmunol.org/content/166/12/7033 http://www.jimmunol.org/ References This article cites 51 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/166/12/7033.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 24, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Infection of Human Macrophages and Dendritic Cells with Mycobacterium tuberculosis Induces a Differential Cytokine Gene Expression That Modulates T Cell Response1 Elena Giacomini,* Elisabetta Iona,† Lucietta Ferroni,* Minja Miettinen,‡ Lanfranco Fattorini,† Graziella Orefici,† Ilkka Julkunen,‡ and Eliana M.
    [Show full text]
  • Human Fcgr2a / Cd32a (H131) Protein Catalog # AMS.CD1-H5223-100UG for Research Use Only
    Human FcGR2A / CD32a (H131) Protein Catalog # AMS.CD1-H5223-100UG For Research Use Only Description Source Human FcGR2A / CD32a (H131) Protein,also called Human FcGR2A / CD32a Protein (167 His), Ala 36 - Ile 218 (Accession # P12318-1), was produced in human 293 cells (HEK293) Predicted N-terminus Ala 36 Protein Structure Molecular Human FcGR2A / CD32a (H131), His Tag is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 21.1 Characterization kDa. The predicted N-terminus is Ala 36. The reducing (R) protein migrates as 29-32 kDa in SDS-PAGE due to glycosylation. Endotoxin Less than 1.0 EU per μg by the LAL method. >95% as determined by SDS-PAGE. Purity Bioactivity The bioactivity is measured by its binding ability to Ipilimumab in a SPR assay. Immobilized Human FcGR2A / CD32a (H131), His Tag (Cat# AMS.CD1-H5223-100UG) can bind Ipilimumab with affinity constant of around 2.7 uM. Measured by its binding ability in a functional ELISA. Immobilized human IgG4 at 10μg/mL (100 µl/well),can bind Human FcGR2A / CD32a (H131), His Tag (Cat# AMS.CD1-H5223-100UG) with a linear of 0.1-2 μg/mL. Formulation and Storage Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation. Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the Reconstitution reconstitution protocol provided in the COA. Storage For long term storage, the product should be stored at lyophilized state at -20°C or lower.
    [Show full text]
  • The Role of the CD58 Locus in Multiple Sclerosis
    The role of the CD58 locus in multiple sclerosis Philip L. De Jagera,b,c,1, Clare Baecher-Allana, Lisa M. Maiera,c, Ariel T. Arthurd, Linda Ottobonia,c, Lisa Barcellose, Jacob L. McCauleyf, Stephen Sawcerg, An Gorish, Janna Saarelai, Roman Yelenskyc,j, Alkes Pricec,k, Virpi Leppai, Nick Pattersonc, Paul I. W. de Bakkerb,c, Dong Trana,c, Cristin Aubina,c, Susan Pobywajloa, Elizabeth Rossina,c, Xinli Huc, Charles W. Ashleya, Edwin Choyc,j, John D. Riouxc,l, Margaret A. Pericak-Vancef, Adrian Ivinsonm, David R. Boothn, Graeme J. Stewartn, Aarno Palotiec,h, Leena Peltonenc,h,Be´ ne´ dicte Duboisg, Jonathan L. Haineso, Howard L. Weinera, Alastair Compstong, Stephen L. Hauserp,q, Mark J. Dalyc,j, David Reichc,j, Jorge R. Oksenbergp,q, and David A. Haflera,c. aDivision of Molecular Immunology, Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115; bPartners Center for Personalized Genetic Medicine, Boston, MA 02115; cProgram in Medical and Population Genetics, Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA 02139; dDepartment of Medicine and the Nerve Research Foundation, University of Sydney, Sydney NSW 2145, Australia; eDivision of Epidemiology, School of Public Health, University of California, Berkeley, CA 94720-7360; fMiami Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL 33136; gDepartment of Clinical Neurosciences, Addenbrooke’s Hospital, University of Cambridge, Box 165, Hills Road, Cambridge CB2 2QQ,
    [Show full text]
  • Understanding the Synergy of Nkp46 and Co-Activating Signals in Various NK Cell Subpopulations: Paving the Way for More Successful NK-Cell-Based Immunotherapy
    cells Article Understanding the Synergy of NKp46 and Co-Activating Signals in Various NK Cell Subpopulations: Paving the Way for More Successful NK-Cell-Based Immunotherapy 1,2, 3, 1, 1 Loris Zamai * , Genny Del Zotto y , Flavia Buccella y, Sara Gabrielli , Barbara Canonico 1 , Marco Artico 4, Claudio Ortolani 1 and Stefano Papa 1 1 Department of Biomolecular Sciences, University of Urbino “Carlo Bo”, 61032 Urbino, Italy; fl[email protected] (F.B.); [email protected] (S.G.); [email protected] (B.C.); [email protected] (C.O.); [email protected] (S.P.) 2 INFN-Gran Sasso National Laboratory, Assergi, 67100 L’Aquila, Italy 3 Area Aggregazione Servizi e Laboratori Diagnostici, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy; [email protected] 4 Department of Sensory Organs, Sapienza University of Rome, 00161 Rome, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0722-304319; Fax: +39-0722-304319 These authors contributed equally. y Received: 11 February 2020; Accepted: 13 March 2020; Published: 19 March 2020 Abstract: The NK cell population is characterized by distinct NK cell subsets that respond differently to the various activating stimuli. For this reason, the determination of the optimal cytotoxic activation of the different NK cell subsets can be a crucial aspect to be exploited to counter cancer cells in oncologic patients. To evaluate how the triggering of different combination of activating receptors can affect the cytotoxic responses of different NK cell subsets, we developed a microbead-based degranulation assay. By using this new assay, we were able to detect CD107a+ degranulating NK cells even within the less cytotoxic subsets (i.e., resting CD56bright and unlicensed CD56dim NK cells), thus demonstrating its high sensitivity.
    [Show full text]
  • The B7/BB1 Antigen Provides One of Several Costimulatory Signals for the Activation of CD4+ T Lymphocytes by Human Blood Dendritic Cells in Vitro
    Amendment history: Correction (April 1993) The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J W Young, … , R M Steinman, B Dupont J Clin Invest. 1992;90(1):229-237. https://doi.org/10.1172/JCI115840. Research Article T cells respond to peptide antigen in association with MHC products on antigen-presenting cells (APCs). A number of accessory or costimulatory molecules have been identified that also contribute to T cell activation. Several of the known accessory molecules are expressed by freshly isolated dendritic cells, a distinctive leukocyte that is the most potent APC for the initiation of primary T cell responses. These include ICAM-1 (CD54), LFA-3 (CD58), and class I and II MHC products. Dendritic cells also constitutively express the accessory ligand for CD28, B7/BB1, which has not been previously identified on circulating leukocytes freshly isolated from peripheral blood. Dendritic cell expression of both B7/BB1 and ICAM-1 (CD54) increases after binding to allogeneic T cells. Individual mAbs against several of the respective accessory T cell receptors, e.g., anti-CD2, anti-CD4, anti-CD11a, and anti-CD28, inhibit T cell proliferation in the dendritic cell-stimulated allogeneic mixed leukocyte reaction (MLR) by 40-70%. Combinations of these mAbs are synergistic in achieving near total inhibition. Other T cell-reactive mAbs, e.g., anti-CD5 and anti-CD45, are not inhibitory. Lymphokine secretion and blast transformation are similarly reduced when active accessory ligand-receptor interactions are blocked in the dendritic cell-stimulated allogeneic […] Find the latest version: https://jci.me/115840/pdf The B7/BB1 Antigen Provides One of Several Costimulatory Signals for the Activation of CD4+ T Lymphocytes by Human Blood Dendritic Cells In Vitro James W.
    [Show full text]
  • Immunology Focus Summer | 2006 Immunology FOCUS
    R&D Systems Immunology Focus summer | 2006 Immunology FOCUS Inside page 2 Signal Transduction: Kinase & Phosphatase Reagents page 3 Lectin Family page 4 Regulatory T Cells page 5 Natural Killer Cells page 6 Innate Immunity & Dendritic Cells page 7 Co-Stimulation/-Inhibition The B7 Family & Associated Molecules page 8 Proteome Profiler™ Phospho-Immunoreceptor Array ITAM/ITIM-Associated Receptors www.RnDSystems.com Please visit our website @ www.RnDSystems.com for product information and past issues of the Focus Newsletter: Cancer, Neuroscience, Cell Biology, and more. Quality | Selec tion | Pe rformance | Result s Cancer Development Endocrinology Immunology Neuroscience Proteases Stem Cells Signal Transduction: Kinase & Phosphatase Reagents Co-inhibitory PD-L2/PD-1 signaling & SHP-2 phosphatase KINASE & PHOSPHATASE RESEARCH REAGENTS Regulation of MAP kinase (MAPK) signaling Kinases Phosphatases pathways is critical for T cell development, MOLECULE ANTIBODIES ELISAs/ASSAYS MOLECULE ANTIBODIES ELISAs/ASSAYS activation, differentiation, and death. MAPKs Akt Family H M R H M R Alkaline Phosphatase* H M R are activated by the dual phosphorylation of threonine and tyrosine residues resulting in AMPK H M R Calcineurin A, B H M R subsequent transcription factor activation. ATM H M R H CD45 H M H M The MAPK signaling pathway in T cells can be CaM Kinase II Ms CDC25A, B* H M R triggered by cytokines, growth factors, and CDC2 H M R DARPP-32 M R ligands for transmembrane receptors. Chk1, 2 H M R H M R DEP-1/CD148* H M R H Ligation of the T cell receptor (TCR)/CD3 ERK1, 2 H M R H M R LAR H M R complex results in rapid activation of PI 3- kinase, which leads to Akt and MAPK ERK3 H Lyp H activation.
    [Show full text]
  • Gene CD58 Human Basis for Alternative Mrna Splicing of The
    Gene Structure, Promoter Characterization, and Basis for Alternative mRNA Splicing of the Human CD58 Gene This information is current as Reinhard Wallich, Christiane Brenner, Yvonne Brand, Matthias of September 23, 2021. Roux, Manuel Reister and Stefan Meuer J Immunol 1998; 160:2862-2871; ; http://www.jimmunol.org/content/160/6/2862 Downloaded from References This article cites 60 articles, 24 of which you can access for free at: http://www.jimmunol.org/content/160/6/2862.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 23, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1998 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Gene Structure, Promoter Characterization, and Basis for Alternative mRNA Splicing of the Human CD58 Gene1 Reinhard Wallich,2 Christiane Brenner, Yvonne Brand, Matthias Roux, Manuel Reister, and Stefan Meuer The 60-kDa lymphocyte function-associated Ag-3 (LFA-3/CD58), a highly glycosylated adhesion molecule that serves as ligand for the T cell-restricted glycoprotein CD2, is encoded by a gene at the human chromosome locus 1p13.
    [Show full text]